2021 CMSC Annual Meeting

Go back to the CMSC Education Website
Search

Tag: Knoxville

Poster-Disease-modifying Therapy

October 25, 2021

Agnos Study Design: A Phase 4 Study Assessing Ofatumumab in Treatment-Naïve Young Adults with Early Relapsing Remitting MS Benchmarked Against Healthy Controls

Background: Early intervention with high efficacy therapies has been shown to reduce long-term disability accrual in patients with multiple...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Safety and Effectiveness of Peginterferon Beta-1a in a Subgroup of African American Patients: Plegridy Observational Program Interim Analysis

Background: Limited data on baseline (BL) characteristics and disease severity exist for Black/African American (AA) patients with multiple...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Treatment Persistence, Safety, Tolerability, and Effectiveness of Diroximel Fumarate in the Real-World: Design of the Phase 4 Experience–US Study

Background: Diroximel fumarate (DRF) is an oral fumarate approved in the United States (US) for relapsing multiple sclerosis (MS). DRF...

Read More →

Platform-Disease Modifying Therapies

October 25, 2021

Efficacy and Safety of Ublituximab Versus Teriflunomide in Relapsing Multiple Sclerosis: Results of the Phase 3 Ultimate I and II Trials

Background: Ublituximab, a novel monoclonal antibody, targets a unique epitope on the CD20 antigen and is glycoengineered for enhanced...

Read More →
MAILING ADDRESS

3 University Plaza Drive, Ste 116
Hackensack, NJ 07601

CONTACT US

(201) 487-1050
info@mscare.org

FOLLOW US
Facebook-f Twitter Linkedin Youtube

© 2021 CMSC